On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...

With two complete response letters in the rearview mirror, Abbvie Inc.’s Vyalev (foscarbidopa/foslevodopa) has been approved by the U.S. FDA for treating Parkinson’s disease. The drug is the first ...

Nyxoah SA recently raised $27 million after selling three million shares in a bid to shore up its capital base as it prepares to commercialize Genio — its obstructive sleep apnea technology — in the U ...

Each year, the organization highlights promising early-stage companies that have the potential to disrupt the market in the near future — and this year, Canadian ventures make up more than a tenth of ...